Abeona Therapeutics Inc vs Wells Fargo & Co — how do they compare? Abeona Therapeutics Inc trades at $7.57 (market cap $421.19M), while Wells Fargo & Co trades at $87.35 (market cap $264.66B). The key difference: Wells Fargo & Co is far larger — about 628.4× Abeona Therapeutics Inc's market cap, and Wells Fargo & Co pays a 2.29% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | WFC | |
|---|---|---|
Market Cap | $421.19M | $264.66B |
Sector | Health | Financials |
52-Week High | $7.45 | $96.40 |
52-Week Low | $4.17 | $73.42 |
Enterprise Value | $276.10M | — |
Dividend Yield | — | 2.29% |
Trailing returns across standard periods
Latest headlines on both assets
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →Wells Fargo is one of the largest banks in the United States, with approximately $1.9 trillion in balance sheet assets. The company is split into four primary segments: consumer banking, commercial banking, corporate and investment banking, and wealth and investment management. It is almost entirely focused on the U.S.
Read more on WFC →